Comparison of Effects of Telmisartan and Valsartan on Late Lumen Loss and Inflammatory Markers After Sirolimus-Eluting Stent Implantation in Hypertensive Patients

American Journal of Cardiology

Volumn 100, Issue 11, 2007, Pages 1625-1629

  Hong, Soon Jun ^a   Shim, Wan Joo ^a   Choi, Jong Il ^a   Joo, Hyung Joon ^a   Shin, Seung Yong ^a   Park, Seong Mi ^a   Lim, Sang Yup ^a   Lim, Do Sun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICORANDIL; NITRATE; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADULT; ARTERY DIAMETER; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIZZINESS; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SMOKING; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SIROLIMUS; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VALINE;

EID: 36248953701     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.068     Document Type: Article

References (14)

1. Battershill A.J., and Scott L.J. Telmisartan: a review of its use in the management of hypertension. Drugs 66 (2006) 51-83
2. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
3. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 (2004) 993-1002
4. Koulouris S., Symeonides P., Triantafyllou K., Ioannidis G., Karabinos I., Katostaras T., El-Ali M., Theodoridis T., Vratsista E., Thalassinos N., et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 95 (2005) 1386-1388
5. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
6. Holmes Jr. D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., Brown C., Fischell T., Wong S.C., Midei M., Snead D., and Kuntz R.E. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
7. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., Roccella E.J., and National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
8. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., and Leon M.B. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
9. Moussa I., Leon M.B., Baim D.S., O'Neill W.W., Popma J.J., Buchbinder M., Midwall J., Simonton C.A., Keim E., Wang P., Kuntz R.E., and Moses J.W. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 (2004) 2273-2278
10. Ryan T.J., Bauman W.B., Kennedy J.W., Kereiakes D.J., King III S.B., McCallister B.D., Smith Jr. S.C., and Ullyot D.J. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 88 (1993) 2987-3007
11. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115 (2005) 911-919
12. Devaraj S., O'Keefe G., and Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 90 (2005) 4549-4554
13. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through camp-dependent pathway. Circulation 102 (2000) 1296-1301
14. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., and Okamoto Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063